<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Genomics Inform</journal-id>
      <journal-id journal-id-type="iso-abbrev">Genomics Inform</journal-id>
      <journal-id journal-id-type="publisher-id">GNI</journal-id>
      <journal-title-group>
        <journal-title>Genomics &amp; Informatics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1598-866X</issn>
      <issn pub-type="epub">2234-0742</issn>
      <publisher>
        <publisher-name>Korea Genome Organization</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28638310</article-id>
      <article-id pub-id-type="pmc">5478708</article-id>
      <article-id pub-id-type="doi">10.5808/GI.2017.15.2.56</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Analysis of Gene Expression in Human Dermal Fibroblasts Treated with Senescence-Modulating COX Inhibitors</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Han</surname>
            <given-names>Jeong A.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="FN1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Jong-Il</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="corresp" rid="FN1">**</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Biochemistry and Molecular Biology, Kangwon National University School of Medicine, Chuncheon 24341, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Korea.</aff>
      <aff id="A3"><label>3</label>Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.</aff>
      <aff id="A4"><label>4</label>Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 03080, Korea.</aff>
      <author-notes>
        <corresp id="FN1"><sup>*</sup>Corresponding author1: Tel: +82-33-250-8832, Fax: +82-33-250-8807, <email>gshja@kangwon.ac.kr</email></corresp>
        <corresp id="FN2"><sup>**</sup>Corresponding author2: Tel: +82-2-740-8251, Fax: +82-2-744-4534, <email>jongil@snu.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>6</month>
        <year>2017</year>
      </pub-date>
      <volume>15</volume>
      <issue>2</issue>
      <fpage>56</fpage>
      <lpage>64</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>3</month>
          <year>2017</year>
        </date>
        <date date-type="rev-recd">
          <day>02</day>
          <month>5</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>5</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2017 by the Korea Genome Organization</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>It is identical to the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We have previously reported that NS-398, a cyclooxygenase-2 (COX-2)&#x2013;selective inhibitor, inhibited replicative cellular senescence in human dermal fibroblasts and skin aging in hairless mice. In contrast, celecoxib, another COX-2&#x2013;selective inhibitor, and aspirin, a non-selective COX inhibitor, accelerated the senescence and aging. To figure out causal factors for the senescence-modulating effect of the inhibitors, we here performed cDNA microarray experiment and subsequent Gene Set Enrichment Analysis. The data showed that several senescence-related gene sets were regulated by the inhibitor treatment. NS-398 up-regulated gene sets involved in the tumor necrosis factor &#x3B2; receptor pathway and the fructose and mannose metabolism, whereas it down-regulated a gene set involved in protein secretion. Celecoxib up-regulated gene sets involved in G2M checkpoint and E2F targets. Aspirin up-regulated the gene set involved in protein secretion, and down-regulated gene sets involved in RNA transcription. These results suggest that COX inhibitors modulate cellular senescence by different mechanisms and will provide useful information to understand senescence-modulating mechanisms of COX inhibitors.</p>
      </abstract>
      <kwd-group>
        <kwd>cyclooxygenase 2</kwd>
        <kwd>fibroblast</kwd>
        <kwd>gene set enrichment analysis</kwd>
        <kwd>inhibitor</kwd>
        <kwd>senescence</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Prostaglandin endoperoxide synthase, also called as cyclooxygenase (COX), is an enzyme converting arachidonic acid to prostaglandin H<sub>2</sub> (PGH<sub>2</sub>). PGH<sub>2</sub> is a common precursor for prostanoid biosynthesis such as PGD<sub>2</sub>, PGE<sub>2</sub>, PGF<sub>2</sub>&#x3B1;, PGI<sub>2</sub>, and thromboxane A<sub>2</sub>. These prostanoids are known to be important chemical mediators for inflammation as well as other biological processes [<xref rid="B1" ref-type="bibr">1</xref>]. There are two isoforms of COX. COX-1 (<italic>PTGS1</italic>) is expressed constitutively in most cells and responsible for basal level of prostanoid biosynthesis. COX-2 (<italic>PTGS2</italic>) is induced by various stimuli such as bacterial endotoxins, cytokines, genotoxic agents, growth factors, or oncogene products [<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref>].</p>
      <p>Most non-steroidal anti-inflammatory drugs are COX inhibitors. These drugs inhibit the COX catalytic activity by occupying the active site of COX. Aspirin, ibuprofen, or flurbiprofen is a non-selective COX inhibitor, which inhibits both COX-1 and COX-2 catalytic activity. In contrast, NS-398, celecoxib, or nimesulide is a selective COX-2 inhibitor, which inhibits COX-2 catalytic activity specifically [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>].</p>
      <p>The mechanism of aging has not been fully understood. However, it has been proposed that the pro-inflammatory catalytic activity of COX-2 is a causal factor for aging. The hypothesis proposes that reactive oxygen species (ROS) generated in the process of normal metabolism or inflammation activate the transcription factor nuclear factor &#x3BA;B (NF-&#x3BA;B). NF-&#x3BA;B increases the transcription of pro-inflammatory target genes such as COX-2, which in turn stabilizes a chronic inflammatory circuit by generating ROS. This chronic inflammation causes tissue damage and aging [<xref rid="B5" ref-type="bibr">5</xref>].</p>
      <p>If the pro-inflammatory catalytic activity of COX-2 is a causal factor for aging, COX-2 inhibitors should conceivably inhibit aging. In this context, we have previously examined the effect of COX-2 inhibitors on aging both in the replicative cellular senescence model of human dermal fibroblasts (HDFs) and in the intrinsic skin aging model of hairless mice. We observed that among three selective COX-2 inhibitors studied, only NS-398 inhibited the cellular senescence whereas celecoxib and nimesulide accelerated the senescence. In addition, three non-selective COX inhibitors including aspirin, ibuprofen, and flurbiprofen accelerated the senescence [<xref rid="B6" ref-type="bibr">6</xref>]. Also, we observed that only NS-398 inhibited the skin aging while celecoxib and aspirin accelerated the skin aging in hairless mice [<xref rid="B3" ref-type="bibr">3</xref>]. These studies strongly suggest that the pro-inflammatory catalytic activity of COX-2 is not a causal factor for aging and that the aging-modulating effect of COX inhibitors is attributable to a catalytic activity&#x2013;independent mechanism.</p>
      <p>In an attempt to figure out underlying mechanisms by which COX inhibitors modulate aging, we here performed cDNA microarray experiment and subsequent Gene Set Enrichment Analysis (GSEA) in HDFs treated with three COX inhibitors, NS-398, celecoxib, and aspirin.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <sec>
        <title>Materials and cell culture</title>
        <p>NS-398 and aspirin were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Celecoxib was a generous gift from Dr. S.V. Yim (Kyung Hee University, Seoul, Korea). HDFs, isolated from foreskin [<xref rid="B7" ref-type="bibr">7</xref>], were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA), penicillin (100 units/mL) and streptomycin (100 units/mL) in a 5% CO<sub>2</sub> incubator [<xref rid="B6" ref-type="bibr">6</xref>].</p>
      </sec>
      <sec>
        <title>RNA isolation</title>
        <p>Total RNA was extracted from HDFs with Trizol (Life Technologies), purified with the addition of chloroform, and precipitated with the addition of isopropanol. The RNA concentration was determined by spectrophotometer and the quality of RNA was evaluated by OD 260/280 ratio and gel electrophoresis [<xref rid="B8" ref-type="bibr">8</xref>].</p>
      </sec>
      <sec>
        <title>cDNA microarray experiment</title>
        <p>The following procedures were carried out by Macrogen Co. (Seoul, Korea). Five hundred fifty nanograms of total RNA was reverse-transcribed to cDNA using a T7 oligo(dT) primer. Second-strand cDNA was synthesized, <italic>in vitro</italic> transcribed, and labeled with biotin-NTP. After purification, 750 ng of labeled cRNA was hybridized to Illumina Human HT12 v.4 bead array (Illumina, San Diego, CA, USA) for 16-18 h at 58oC. The array signal was detected by using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK). Arrays were scanned with an Illumina bead array Reader confocal scanner. Array data were filtered by detection p-value &lt; 0.05 (similar to signal to noise). The average signal values of filtered genes were transformed by logarithm and normalized by the quantile method [<xref rid="B8" ref-type="bibr">8</xref>].</p>
      </sec>
      <sec>
        <title>Gene Set Enrichment Analysis (GSEA)</title>
        <p>The beta version of GSEA software and MSigDB 5.2 were downloaded from the Broad Institute (<ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/index.jsp">http://software.broadinstitute.org/gsea/index.jsp</ext-link>). GSEA was carried out as described previously [<xref rid="B9" ref-type="bibr">9</xref>]. Enrichment of gene sets was considered statistically significant if the normalized p-value was &lt; 0.01 and the false discovery rate (FDR) was &lt; 0.20.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <sec>
        <title>Treatment of HDFs with COX inhibitors</title>
        <p>We have previously shown that among COX inhibitors studied, NS-398, a COX-2-selective inhibitor, inhibited replicative cellular senescence in HDFs as well as skin aging in hairless mice, whereas celecoxib, another COX-2-selective inhibitor, and aspirin, a non-selective COX inhibitor, accelerated the senescence and aging. At that time, we treated cells or skin with inhibitors every day for more than a month (<xref ref-type="table" rid="T1">Table 1</xref>) [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B6" ref-type="bibr">6</xref>].</p>
        <p>To figure out causal factors for the senescence-modulating effect of the inhibitors, we treated HDFs with NS-398, celecoxib, aspirin, or dimethyl sulfoxide (DMSO) (the vehicle) every day for only 3 days in this study. The IC<sub>50</sub> values have been reported for recombinant human COX-1 and COX-2 of NS-398 and celecoxib [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref>], and for recombinant ovine COX-1 and COX-2 of aspirin [<xref rid="B12" ref-type="bibr">12</xref>]. In the case of NS-398 and celecoxib, we used approximately 10-fold higher concentration of IC<sub>50</sub> to inhibit COX-2 catalytic activity sufficiently. NS-398 and celecoxib showed no acute cellular toxicity at this concentration. In the case of aspirin, however, we used IC<sub>50</sub> because 10-fold higher concentration caused acute cellular toxicity (<xref ref-type="table" rid="T1">Table 1</xref>) [<xref rid="B6" ref-type="bibr">6</xref>].</p>
      </sec>
      <sec>
        <title>DNA microarray and GSEA</title>
        <p>We performed cDNA microarray experiment using RNA extracted from the drug-treated HDFs. Among 47,319 probe sets, 20,271 probe sets passed the criteria of the detection p-value &lt; 0.05. Unsupervised hierarchical cluster analysis showed that drug-treated cells were well segregated in the order of DMSO, NS-398, celecoxib, and aspirin (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
        <p>To figure out underlying mechanisms by which COX inhibitors modulate senescence, we performed GSEA using 17,777 probe sets having all information including gene symbols and gene descriptions. We sorted the data sets based on the value of (I<sub>NS-398</sub> &#x2013; I<sub>DMSO</sub>) for the comparison of NS-398 versus DMSO; the value of (I<sub>Celecoxib</sub> &#x2013; I<sub>DMSO</sub>) for the comparison of celecoxib versus DMSO; and the value of (I<sub>Aspirin</sub> &#x2013; I<sub>DMSO</sub>) for the comparison of aspirin versus DMSO to rank the data sets as described previously [<xref rid="B9" ref-type="bibr">9</xref>].</p>
        <p>We then tested (1) the Hallmark gene sets (H); (2) gene sets regulating canonical pathways&#x2014;i.e., Biocarta gene sets (C2:CP:BIOCARTA), Kyoto Encyclopedia of Genes and Genomes (KEGG) gene sets (C2:CP:KEGG), and Reactome gene sets (C2:CP:REACTOME); and (3) gene ontology gene sets&#x2014;i.e., biological process gene sets (G5:BP), cellular component gene sets (G5:CC), and molecular function gene sets (G5:MF).</p>
      </sec>
      <sec>
        <title>NS-398 versus DMSO</title>
        <p>The analysis of NS-398 versus DMSO showed that two gene sets are enriched in NS-398&#x2013;treated HDFs as compared with DMSO-treated HDFs. These gene sets consist of genes regulating the tumor necrosis factor beta receptor (TNFR2) pathway and the fructose and mannose metabolism (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F2">Fig. 2A</xref>). Enriched genes in each pathway were shown in <xref ref-type="supplementary-material" rid="S3">Supplementary Tables 1</xref> and <xref ref-type="supplementary-material" rid="S4">2</xref>, and <xref ref-type="supplementary-material" rid="S1">Supplementary Figs. 1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>.</p>
        <p>On the other hand, four gene sets were enriched in DMSO-treated HDFs as compared with NS-398&#x2013;treated HDFs: genes down-regulated in response to ultraviolet (UV) radiation, and genes regulating the protein secretion, the trefoil factor pathway and the receptor-regulated Smads (R-SMAD) binding (<xref ref-type="table" rid="T3">Table 3</xref>, <xref ref-type="fig" rid="F2">Fig. 2B</xref>). Enriched genes in each gene set were shown in <xref ref-type="supplementary-material" rid="S5">Supplementary Tables 3</xref>, <xref ref-type="supplementary-material" rid="S6">4</xref>, <xref ref-type="supplementary-material" rid="S7">5</xref>, <xref ref-type="supplementary-material" rid="S8">6</xref>.</p>
      </sec>
      <sec>
        <title>Celecoxib versus DMSO</title>
        <p>The analysis of celecoxib versus DMSO showed that four gene sets were enriched in celecoxib-treated HDFs as compared with DMSO-treated HDFs. These gene sets consist of genes involved in the G2M checkpoint, E2F targets, &#x3B3; tubulin complex and the four way junction (Holliday junction) DNA binding (<xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="fig" rid="F3">Fig. 3A</xref>). Enriched genes in each gene set were shown in <xref ref-type="supplementary-material" rid="S9">Supplementary Tables 7</xref>, <xref ref-type="supplementary-material" rid="S10">8</xref>, <xref ref-type="supplementary-material" rid="S11">9</xref>, <xref ref-type="supplementary-material" rid="S12">10</xref>.</p>
        <p>On the other hand, one gene set was enriched in DMSO-treated HDFs as compared with celecoxib-treated HDFs. This gene set consists of genes regulating olfactory signaling pathway (<xref ref-type="table" rid="T5">Table 5</xref>, <xref ref-type="fig" rid="F3">Fig. 3B</xref>). The list of enriched genes in this pathway was shown in <xref ref-type="supplementary-material" rid="S13">Supplementary Table 11</xref>.</p>
      </sec>
      <sec>
        <title>Aspirin versus DMSO</title>
        <p>In the case of aspirin versus DMSO, four gene sets were enriched in aspirin-treated HDFs as compared with DMSO-treated HDFs. These gene sets consist of genes involved in the protein secretion, keratin filament and intermediate filament, and genes down-regulated in response to UV radiation (<xref ref-type="table" rid="T6">Table 6</xref>, <xref ref-type="fig" rid="F4">Fig. 4A</xref>). Enriched genes in each gene set were shown in <xref ref-type="supplementary-material" rid="S14">Supplementary Tables 12</xref>, <xref ref-type="supplementary-material" rid="S15">13</xref>, <xref ref-type="supplementary-material" rid="S16">14</xref>, <xref ref-type="supplementary-material" rid="S17">15</xref>.</p>
        <p>On the other hand, three gene sets of C2:CP were enriched in DMSO-treated HDFs as compared with aspirin-treated HDFs: genes regulating prostate cancer, colorectal cancer, and cardiomyopathy (<xref ref-type="table" rid="T7">Table 7</xref>). In addition, 34 gene sets of C5:BP, three gene sets of C5:CC and five gene sets of C5:MF were enriched in DMSO-treated HDFs as compared with aspirin-treated HDFs. These gene sets consist of genes involved in embryonic development, negative regulation of protein localization to plasma membrane, DNA-dependent RNA transcription, cell differentiation, glutamate receptor binding, or Smad binding (<xref ref-type="table" rid="T7">Tables 7</xref> and <xref ref-type="table" rid="T8">8</xref>, <xref ref-type="fig" rid="F4">Fig. 4B</xref>). Of note, the gene set involved in platelet aggregation was enriched in DMSO-treated HDFs as compared with aspirin-treated HDFs (<xref ref-type="table" rid="T8">Table 8</xref>, FDR, 0.179). Enriched genes in representative gene sets were shown in <xref ref-type="supplementary-material" rid="S18">Supplementary Tables 16</xref>, <xref ref-type="supplementary-material" rid="S19">17</xref>, <xref ref-type="supplementary-material" rid="S20">18</xref>, <xref ref-type="supplementary-material" rid="S21">19</xref>, <xref ref-type="supplementary-material" rid="S22">20</xref>, <xref ref-type="supplementary-material" rid="S23">21</xref>, <xref ref-type="supplementary-material" rid="S24">22</xref>.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Our data showed that NS-398 treatment up-regulated the gene set involved in the TNFR2 pathway (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F2">Fig. 2A</xref>, <xref ref-type="supplementary-material" rid="S3">Supplementary Table 1</xref>). This pathway is well known to activate the NF-&#x3BA;B signaling that mediates cell proliferation, anti-apoptosis, inflammation, differentiation, or development (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 1</xref>) [<xref rid="B13" ref-type="bibr">13</xref>]. NF-&#x3BA;B, a transcription factor, has been reported to regulate cellular senescence though its role in the senescence is controversial. Overexpression of c-Rel resulted in premature senescence in normal human keratinocytes [<xref rid="B14" ref-type="bibr">14</xref>]. On the contrary, mouse embryonic fibroblasts from NF-&#x3BA;B1 knockout mice showed enhanced cellular senescence [<xref rid="B15" ref-type="bibr">15</xref>]. In addition, siRNA against NF-&#x3BA;B2 or RelB induced premature senescence in HDFs in a p53-dependent manner [<xref rid="B16" ref-type="bibr">16</xref>]. These studies suggest that the anti-senescent effect of NS-398 might be attributable to a regulation of NF-&#x3BA;B signaling.</p>
      <p>NS-398 treatment also up-regulated the gene set involved in the fructose and mannose metabolism (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="supplementary-material" rid="S4">Supplementary Table 2</xref>). This metabolic pathway leads to enhanced glycolysis and N-glycan biosynthesis (<xref ref-type="supplementary-material" rid="S2">Supplementary Fig. 2</xref>). Alterations of glucose metabolism have been reported in cellular senescence though the data is conflicting. In human mammary epithelial cells, B-Raf&#x2013;induced premature senescence was associated with a reduction of glucose uptake, and overexpression of hexokinase 2 prevented the oncogene-induced senescence [<xref rid="B17" ref-type="bibr">17</xref>]. On the contrary, glucose consumption and hexokinase activity were increased in senescent HDFs as compared to young HDFs [<xref rid="B18" ref-type="bibr">18</xref>]. These studies suggest that NS-398 might delay cellular senescence via regulation of glycolysis.</p>
      <p>It is intriguing that the gene set involved in protein secretion is down-regulated by NS-398 treatment but is up-regulated by aspirin treatment (<xref ref-type="table" rid="T3">Tables 3</xref> and <xref ref-type="table" rid="T6">6</xref>, <xref ref-type="fig" rid="F2">Figs. 2B</xref> and <xref ref-type="fig" rid="F4">4A</xref>, <xref ref-type="supplementary-material" rid="S6">Supplementary Tables 4</xref> and <xref ref-type="supplementary-material" rid="S14">12</xref>). It has been reported that cellular senescence is accompanied by an increase in the secretion of intercellular signaling molecules including interleukins, chemokines, growth factors, proteases, and extracellular matrix proteins [<xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref>]. For example, production of interleukin-1, -6, chemokine (C-C motif) ligand-1, -2, -3, -7, -8, -12, -13, -16, -20, -26, chemokine (C-X-C motif) ligand-1, -2, -4, -5, -6, -8, insulin-like growth factor binding protein-2, -3, -4, -5, -6, -7, connective tissue growth factor, granulocyte-macrophage colony-stimulating factor, granulocyte colony stimulating factor, matrix metalloproteinase-1, -3, -10, plasminogen activator inhibitor 1, or fibronectin increased in senescent HDFs as compared to in young HDFs [<xref rid="B21" ref-type="bibr">21</xref>]. Ectopic expression of chemokine receptors such as CXCR1 or CXCR2 induced premature senescence in HDFs [<xref rid="B22" ref-type="bibr">22</xref>]. Extracellular matrix from young HDFs restored senescent HDFs to an apparently youthful state [<xref rid="B23" ref-type="bibr">23</xref>]. In addition, there is a report that p16-induced senescence is accompanied by an increase in the glucose-stimulated insulin secretion in mouse and human pancreatic beta cells [<xref rid="B24" ref-type="bibr">24</xref>]. These studies suggest that regulation of protein secretion might be an important common mechanism by which NS-398 delays but aspirin accelerates cellular senescence.</p>
      <p>In addition to the up-regulation of protein secretion, aspirin down-regulated gene sets involved in DNA-dependent RNA transcription (<xref ref-type="table" rid="T7">Table 7</xref>, FDR, 0.062 and 0.088; <xref ref-type="table" rid="T8">Table 8</xref>, FDR, 0.061 and 0.197; <xref ref-type="fig" rid="F4">Fig. 4B</xref>). Compatible with these results, a cDNA microarray study reported that genes involved in transcription were down-regulated specifically during senescence in HDFs [<xref rid="B25" ref-type="bibr">25</xref>]. In addition, there is a report that RNA transcription was decreased in aged rat brain as compared to in young rat brain [<xref rid="B26" ref-type="bibr">26</xref>]. Therefore, aspirin might accelerate cellular senescence by downregulation of DNA-dependent RNA transcription.</p>
      <p>It is well known that aspirin inhibits platelet aggregation and thereby thrombus formation [<xref rid="B27" ref-type="bibr">27</xref>]. Consistent with this, our data showed that the gene set involved in platelet aggregation was down-regulated by aspirin treatment (<xref ref-type="table" rid="T8">Table 8</xref>, FDR, 0.179).</p>
      <p>Cyclin-dependent kinase inhibitors (CKIs) are categorized into two families, that is, the Ink4 family including p15, p16, p18, and p19, and the Cip/Kip family including p21, p27, and p57. It has been reported that these CKIs are actively involved in cellular senescence. For example, ectopic expression of p15, p16, p19, p21, or p27 was reported to induce premature senescence in HDFs [<xref rid="B28" ref-type="bibr">28</xref><xref rid="B29" ref-type="bibr">29</xref>]. According to our data, celecoxib treatment up-regulated gene sets relating G2M checkpoint and E2F targets (<xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="fig" rid="F3">Fig. 3A</xref>). In addition, <italic>CDKN1B</italic> encoding p27 and <italic>CDKN2C</italic> encoding p18 were enriched in both gene sets (<xref ref-type="supplementary-material" rid="S9">Supplementary Table 7</xref>, Running enrichment score [ES], 0.410 and 0.274; <xref ref-type="supplementary-material" rid="S10">Supplementary Table 8</xref>, Running ES, 0.299 and 0.193). These data suggest that celecoxib might accelerate cellular senescence through up-regulation of CKIs.</p>
      <p>Collectively, our results suggest that COX inhibitors modulate cellular senescence by different mechanisms though they have the anti-catalytic activity commonly. We believe that our study will provide useful information to understand senescence-modulating mechanisms of COX inhibitors.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ricciotti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>FitzGerald</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
          <article-title>Prostaglandins and inflammation</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <year>2011</year>
          <volume>31</volume>
          <fpage>986</fpage>
          <lpage>1000</lpage>
          <pub-id pub-id-type="pmid">21508345</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Ongusaha</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Ballou</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Mahale</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis</article-title>
          <source>EMBO J</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>5635</fpage>
          <lpage>5644</lpage>
          <pub-id pub-id-type="pmid">12411481</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>WJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclooxygenase-2 inhibitors modulate skin aging in a catalytic activity-independent manner</article-title>
          <source>Exp Mol Med</source>
          <year>2012</year>
          <volume>44</volume>
          <fpage>536</fpage>
          <lpage>544</lpage>
          <pub-id pub-id-type="pmid">22771771</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flower</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>The development of COX2 inhibitors</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2003</year>
          <volume>2</volume>
          <fpage>179</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="pmid">12612644</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Cesari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Anton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marzetti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Giovannini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>AY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular inflammation: underpinnings of aging and age-related diseases</article-title>
          <source>Ageing Res Rev</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>18</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">18692159</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner</article-title>
          <source>Mech Ageing Dev</source>
          <year>2008</year>
          <volume>129</volume>
          <fpage>706</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">18848576</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yeo</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Parka</surname>
              <given-names>JS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Senescence-like changes induced by hydroxyurea in human diploid fibroblasts</article-title>
          <source>Exp Gerontol</source>
          <year>2000</year>
          <volume>35</volume>
          <fpage>553</fpage>
          <lpage>571</lpage>
          <pub-id pub-id-type="pmid">10978678</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
          <article-title>Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines</article-title>
          <source>Genomics Inform</source>
          <year>2014</year>
          <volume>12</volume>
          <fpage>247</fpage>
          <lpage>253</lpage>
          <pub-id pub-id-type="pmid">25705166</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tamayo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mootha</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Mukherjee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ebert</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Gillette</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2005</year>
          <volume>102</volume>
          <fpage>15545</fpage>
          <lpage>15550</lpage>
          <pub-id pub-id-type="pmid">16199517</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barnett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ives</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chiou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Osen</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1994</year>
          <volume>1209</volume>
          <fpage>130</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="pmid">7947975</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penning</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Talley</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Bertenshaw</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Docter</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)</article-title>
          <source>J Med Chem</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>1347</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="pmid">9135032</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Wimsatt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Buckel</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Dyer</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Maddipati</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons</article-title>
          <source>Arch Biochem Biophys</source>
          <year>1995</year>
          <volume>324</volume>
          <fpage>26</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">7503555</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerondakis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fulford</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Messina</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Grumont</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>NF-&#x3BA;B control of T cell development</article-title>
          <source>Nat Immunol</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>15</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">24352326</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gosselin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Monte</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vercamer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bouali</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pourtier</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Involvement of Rel/nuclear factor-kappaB transcription factors in keratinocyte senescence</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>472</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="pmid">14744759</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernal</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Wahlstrom</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Crawley</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Cahill</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Pytel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Loss of Nfkb1 leads to early onset aging</article-title>
          <source>Aging (Albany NY)</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>931</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="pmid">25553648</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iannetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ledoux</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Tudhope</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Sellier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mowla</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of p53 and Rb links the alternative NF-&#x3BA;B pathway to EZH2 expression and cell senescence</article-title>
          <source>PLoS Genet</source>
          <year>2014</year>
          <volume>10</volume>
          <fpage>e1004642</fpage>
          <pub-id pub-id-type="pmid">25255445</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gitenay</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wiel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lallet-Daher</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vindrieux</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aubert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Payen</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence</article-title>
          <source>Cell Death Dis</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>e1089</fpage>
          <pub-id pub-id-type="pmid">24577087</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zwerschke</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mazurek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>St&#xF6;ckl</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>H&#xFC;tter</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Eigenbrodt</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jansen-D&#xFC;rr</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence</article-title>
          <source>Biochem J</source>
          <year>2003</year>
          <volume>376</volume>
          <issue>Pt 2</issue>
          <fpage>403</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">12943534</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coppe</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Patil</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Rodier</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Krtolica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beaus&#xE9;jour</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Parrinello</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen</article-title>
          <source>PLoS One</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>e9188</fpage>
          <pub-id pub-id-type="pmid">20169192</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freund</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Orjalo</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Desprez</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Campisi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory networks during cellular senescence: causes and consequences</article-title>
          <source>Trends Mol Med</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>238</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="pmid">20444648</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Copp&#xE9;</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Desprez</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Krtolica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Campisi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The senescence-associated secretory phenotype: the dark side of tumor suppression</article-title>
          <source>Annu Rev Pathol</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>99</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">20078217</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Acosta</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>O'Loghlen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Banito</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guijarro</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Augert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raguz</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chemokine signaling via the CXCR2 receptor reinforces senescence</article-title>
          <source>Cell</source>
          <year>2008</year>
          <volume>133</volume>
          <fpage>1006</fpage>
          <lpage>1018</lpage>
          <pub-id pub-id-type="pmid">18555777</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Kaeberlein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suh</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Restoration of senescent human diploid fibroblasts by modulation of the extracellular matrix</article-title>
          <source>Aging Cell</source>
          <year>2011</year>
          <volume>10</volume>
          <fpage>148</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="pmid">21108727</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Klochendler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Azazmeh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gabai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Anzi</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion</article-title>
          <source>Nat Med</source>
          <year>2016</year>
          <volume>22</volume>
          <fpage>412</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="pmid">26950362</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2003</year>
          <volume>100</volume>
          <fpage>3251</fpage>
          <lpage>3256</lpage>
          <pub-id pub-id-type="pmid">12626749</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindholm</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Decreased transcription of neuronal polyadenylated RNA during senescence in nuclei from rat brain cortex</article-title>
          <source>J Neurochem</source>
          <year>1986</year>
          <volume>47</volume>
          <fpage>1503</fpage>
          <lpage>1506</lpage>
          <pub-id pub-id-type="pmid">2428935</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Willis</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Aspirin selectively inhibits prostaglandin production in human platelets</article-title>
          <source>Nat New Biol</source>
          <year>1971</year>
          <volume>231</volume>
          <fpage>235</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="pmid">5284361</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McConnell</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Starborg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brookes</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts</article-title>
          <source>Curr Biol</source>
          <year>1998</year>
          <volume>8</volume>
          <fpage>351</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">9512419</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wei</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hemmer</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Sedivy</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Role of p14(ARF) in replicative and induced senescence of human fibroblasts</article-title>
          <source>Mol Cell Biol</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>6748</fpage>
          <lpage>6757</lpage>
          <pub-id pub-id-type="pmid">11564860</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec sec-type="supplementary-material">
      <title>Supplementary materials</title>
      <p>Supplementary data including 22 tables and two figures
can be found with this article online <ext-link ext-link-type="uri" xlink:href="https://www.genominfo.org/src/sm/gni-15-56-s001.pdf">https://www.genominfo.org/src/sm/gni-15-56-s001.pdf</ext-link>.</p>
      <supplementary-material content-type="local-data" id="S1">
        <caption>
          <title>Supplementary Fig. 1</title>
          <p>BIOCARTA_TNFR2_PATHWAY. Enriched genes were highlighted in orange color.</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s001.pdf" orientation="portrait" id="d35e1836" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S2">
        <caption>
          <title>Supplementary Fig. 2</title>
          <p>KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM. Enriched genes were highlighted in orange color. </p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s002.pdf" orientation="portrait" id="d35e1843" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S3">
        <caption>
          <title>Supplementary Table 1</title>
          <p>Enriched genes of BIOCARTA_TNFR2_PATHWAY in NS-398&#x2013;treated HDFs (NS-398 vs. DMSO) </p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s003.pdf" orientation="portrait" id="d35e1850" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S4">
        <caption>
          <title>Supplementary Table 2</title>
          <p>Enriched genes of KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM in NS-398&#x2013;treated HDFs (NS-398 vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s004.pdf" orientation="portrait" id="d35e1857" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S5">
        <caption>
          <title>Supplementary Table 3</title>
          <p>Enriched genes of HALLMARK_UV_RESPONSE_DN in DMSO-treated HDFs (NS-398 vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s005.pdf" orientation="portrait" id="d35e1864" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S6">
        <caption>
          <title>Supplementary Table 4</title>
          <p>Enriched genes of HALLMARK_PROTEIN_SECRETION in DMSO-treated HDFs (NS-398 vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s006.pdf" orientation="portrait" id="d35e1871" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S7">
        <caption>
          <title>Supplementary Table 5</title>
          <p>Enriched genes of BIOCARTA_TFF_PATHWAY in DMSO-treated HDFs (NS-398 vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s007.pdf" orientation="portrait" id="d35e1878" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S8">
        <caption>
          <title>Supplementary Table 6</title>
          <p>Enriched genes of GO_R_SMAD_BINDING in DMSO-treated HDFs (NS-398 vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s008.pdf" orientation="portrait" id="d35e1885" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S9">
        <caption>
          <title>Supplementary Table 7</title>
          <p>Enriched genes of HALLMARK_G2M_CHECKPOINT in celecoxib-treated HDFs (celecoxib vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s009.pdf" orientation="portrait" id="d35e1892" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S10">
        <caption>
          <title>Supplementary Table 8</title>
          <p>Enriched genes of HALLMARK_E2F_TARGETS in celecoxib-treated HDFs (celecoxib vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s010.pdf" orientation="portrait" id="d35e1900" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S11">
        <caption>
          <title>Supplementary Table 9</title>
          <p>Enriched genes of GO_GAMMA_TUBULIN_COMPLEX in Celecoxib-treated HDFs (celecoxib vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s011.pdf" orientation="portrait" id="d35e1907" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S12">
        <caption>
          <title>Supplementary Table 10</title>
          <p>Enriched genes of GO_FOUR_WAY_JUNCTION_DNA_BINDING in celecoxib-treated HDFs (celecoxib vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s012.pdf" orientation="portrait" id="d35e1914" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S13">
        <caption>
          <title>Supplementary Table 11</title>
          <p>Enriched genes of REACTOME_OLFACTORY_SIGNALING_PATHWAY in DMSO-treated HDFs (celecoxib vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s013.pdf" orientation="portrait" id="d35e1921" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S14">
        <caption>
          <title>Supplementary Table 12</title>
          <p>Enriched genes of HALLMARK_PROTEIN_SECRETION in aspirin-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s014.pdf" orientation="portrait" id="d35e1928" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S15">
        <caption>
          <title>Supplementary Table 13</title>
          <p>Enriched genes of HALLMARK_UV_RESPONSE_DN in aspirin-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s015.pdf" orientation="portrait" id="d35e1935" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S16">
        <caption>
          <title>Supplementary Table 14</title>
          <p>Enriched genes of GO_KERATIN_FILAMENT in aspirin-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s016.pdf" orientation="portrait" id="d35e1942" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S17">
        <caption>
          <title>Supplementary Table 15</title>
          <p>Enriched genes of GO_INTERMEDIATE_FILAMENT in aspirin-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s017.pdf" orientation="portrait" id="d35e1949" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S18">
        <caption>
          <title>Supplementary Table 16</title>
          <p>Enriched genes of KEGG_PROSTATE_CANCER in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s018.pdf" orientation="portrait" id="d35e1956" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S19">
        <caption>
          <title>Supplementary Table 17</title>
          <p>Enriched genes of KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s019.pdf" orientation="portrait" id="d35e1963" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S20">
        <caption>
          <title>Supplementary Table 18</title>
          <p>Enriched genes of GO_GENITALIA_DEVELOPMENT in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s020.pdf" orientation="portrait" id="d35e1970" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S21">
        <caption>
          <title>Supplementary Table 19</title>
          <p>Enriched genes of GO_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_PLASMA_MEMBRANE in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s021.pdf" orientation="portrait" id="d35e1978" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S22">
        <caption>
          <title>Supplementary Table 20</title>
          <p>Enriched genes GO_ENDOTHELIAL_CELL_DEVELOPMENT in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s022.pdf" orientation="portrait" id="d35e1985" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S23">
        <caption>
          <title>Supplementary Table 21</title>
          <p>Enriched genes of GO_RNA_POLYMERASE_II_ACTIVATING_TRANSCRIPTION_FACTOR_BINDING in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s023.pdf" orientation="portrait" id="d35e1992" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S24">
        <caption>
          <title>Supplementary Table 22</title>
          <p>Enriched genes of GO_SMAD_BINDING in DMSO-treated HDFs (aspirin vs. DMSO)</p>
        </caption>
        <media mimetype="application" mime-subtype="pdf" xlink:href="gni-15-56-s024.pdf" orientation="portrait" id="d35e1999" position="anchor"/>
      </supplementary-material>
    </sec>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Segregation between the drug-treated HDFs. Unsupervised hierarchical cluster analysis was done between four drug-treated HDFs using 20,271 probe sets with the detection p-value &lt; 0.05.</title>
      </caption>
      <graphic xlink:href="gni-15-56-g001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2</label>
      <caption>
        <title>Enrichment plots (NS-398 vs. DMSO). (A) A representative enriched gene set in NS-398&#x2013;treated HDFs. (B) A representative enriched gene set in DMSO-treated HDFs. DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast.</title>
      </caption>
      <graphic xlink:href="gni-15-56-g002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Fig. 3</label>
      <caption>
        <title>Enrichment plots (celecoxib vs. DMSO). (A) A representative enriched gene set in celecoxib&#x2013;treated HDFs. (B) The representative enriched gene set in DMSO-treated HDFs. DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast.</title>
      </caption>
      <graphic xlink:href="gni-15-56-g003"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Fig. 4</label>
      <caption>
        <title>Enrichment plots (aspirin vs. DMSO). (A) A representative enriched gene set in aspirin-treated HDFs. (B) A representative enriched gene set in DMSO-treated HDFs. DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast.</title>
      </caption>
      <graphic xlink:href="gni-15-56-g004"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <title>Summary of senescence-modulating effect of COX inhibitors and used doses</title>
      </caption>
      <graphic xlink:href="gni-15-56-i001"/>
    </table-wrap>
    <table-wrap id="T2" orientation="portrait" position="float">
      <label>Table 2</label>
      <caption>
        <title>Enriched gene sets in NS-398&#x2013;treated HDFs (NS-398 vs. DMSO)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i002"/>
      <table-wrap-foot>
        <fn>
          <p>HDF, human dermal fibroblast; DMSO, dimethyl sulfoxide; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T3" orientation="portrait" position="float">
      <label>Table 3</label>
      <caption>
        <title>Enriched gene sets in DMSO-treated HDFs (NS-398 vs. DMSO)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i003"/>
      <table-wrap-foot>
        <fn>
          <p>DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T4" orientation="portrait" position="float">
      <label>Table 4</label>
      <caption>
        <title>Enriched gene sets in celecoxib-treated HDFs (celecoxib vs. DMSO)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i004"/>
      <table-wrap-foot>
        <fn>
          <p>HDF, human dermal fibroblast; DMSO, dimethyl sulfoxide; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T5" orientation="portrait" position="float">
      <label>Table 5</label>
      <caption>
        <title>Enriched gene sets in DMSO-treated HDFs (celecoxib vs. DMSO) (C2:Reactome)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i005"/>
      <table-wrap-foot>
        <fn>
          <p>DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T6" orientation="portrait" position="float">
      <label>Table 6</label>
      <caption>
        <title>Enriched gene sets in aspirin-treated HDFs (aspirin vs. DMSO)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i006"/>
      <table-wrap-foot>
        <fn>
          <p>HDF, human dermal fibroblast; DMSO, dimethyl sulfoxide; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T7" orientation="portrait" position="float">
      <label>Table 7</label>
      <caption>
        <title>Enriched gene sets in DMSO-treated HDFs (aspirin vs. DMSO)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i007"/>
      <table-wrap-foot>
        <fn>
          <p>DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T8" orientation="portrait" position="float">
      <label>Table 8</label>
      <caption>
        <title>Enriched gene sets in DMSO-treated HDFs (aspirin vs. DMSO) (C5:BP)</title>
      </caption>
      <graphic xlink:href="gni-15-56-i008"/>
      <table-wrap-foot>
        <fn>
          <p>DMSO, dimethyl sulfoxide; HDF, human dermal fibroblast; NES, normalized enrichment score; FDR, false discovery rate.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>